FDA Approves Rx-to-OTC Switch for Astepro Allergy Nasal Spray
The FDA has approved a prescription to over-the-counter (OTC) switch for Astepro® Allergy (azelastine hydrochloride nasal spray, 0.15%).
Allergic Disorders
Etrasimod Granted Orphan Drug Status for Eosinophilic Esophagitis
Etrasimod is an investigational, next generation, once-daily, oral, highly selective sphingosine 1-phosphate receptor modulator.
Drug-Induced Immunosuppression Examined in US Adults
Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine
SCIT vs SLIT for Allergic Rhinitis: Efficacy Outcomes Compared
Both treatment options were found to be effective for adults with allergic rhinitis or rhinoconjunctivitis.
Case Report Highlights Potential for Severe Infection Following Epinephrine Auto-Injection
The 60-year-old male patient presented to the ED complaining of “the worst pain in his life” in his right thigh.
Guidance Updated for Assessing Allergy Risk of COVID-19 Vaccines
Janssen adenovirus type 26 vectored vaccine may be considered for individuals who self-report PEG allergy
MPR Weekly Dose Podcast 76
In this week’s pod, the FDA review the Emergency Use Authorization for bamlanivimab; Issues are identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID therapy; A novel contraceptive is approved; And Ragwitek has its approval expanded.
Rash Following Medication Change Prompts Evaluation of Excipient Allergy
The patient developed a generalized maculopapular rash approximately 3 hours after receiving warfarin.
Ragwitek Approved for Pediatric Patients With Ragweed Pollen Allergy
The approval was based on data from a phase 3 trial that assessed Ragwitek in 1022 patients 5 to 17 years of age with a history of ragweed-induced rhinoconjunctivitis and sensitivity to short ragweed.
Graded Administration of Second COVID-19 Vaccine Dose After Hypersensitivity
Current recommendations surrounding the administration of the second COVID-19 vaccine dose to patients who experience an immediate hypersensitivity reaction to the first dose are conflicting.
